1. Scrip

AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure

 
• By Emily Hayes

Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.

Cardiogram cardiograph oscilloscope screen blue illustration background

AstraZeneca PLC believes the newly released full results of the DECLARE-TIMI 58 outcomes study support a competitive claim for its SGLT2 inhibitor Farxiga for preventing heart failure hospitalizations, but it still is likely to suffer from efficacy comparisons to Eli Lilly & Co./Boehringer Ingelheim GMBH's SGLT2 inhibitor Jardiance, which met a high bar for reducing cardiovascular events.

The full results of the DECLARE-TIMI 58 outcomes study comparing Farxiga (dapagliflozin) to placebo in 17,160 patients were presented at the American Heart Association (AHA) annual meeting on Nov. 10 in Chicago and published the same day in the New England Journal of Medicine (NEJM) by Stephen Wiviott of Brigham and Women's Hospital and colleagues. Top-line findings were released in September

More from R&D

More from Scrip

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.